Updated:
Óskare Capital
Oskare Capital invests in medical cannabinoid companies and teams. The firm has made 7 investments, including a Series A - II investment in Octarine Bio on...
Óskare Capital
Oskare Capital invests in medical cannabinoid companies and teams. The firm has made 7 investments, including a Series A - II investment in Octarine Bio on January 22, 2026. Founded by Alexandre Ouimet-Storrs.
General information
Firm type
Venture Capital
Year founded
2018
AUM
Undisclosed
Location
Region
Europe
Country
France
City
Paris
Corporate office
108 avenue Felix Faure, 75015 Paris, France
Additional offices
London, United Kingdom
Sector focus
Frequently asked questions
What is Óskare Capital's core investment thesis?
Óskare Capital concentrates on early-stage European deeptech and life sciences companies, with a specific focus on synthetic biology, neurological drug development, chronic pain treatment, and botanical extraction technology. Its disclosed portfolio avoids generalist software and consumer internet plays.
At which stage does Óskare Capital typically invest?
The firm primarily targets Pre-Seed and Seed rounds, with capacity to follow on at Series A or participate in post-IPO opportunities when the underlying science and team align. Its first investment in Octarine Bio was a Pre-Seed check in 2019.
Where is Óskare Capital operationally active?
The firm is headquartered in Paris with an additional office in London. Its portfolio spans Denmark, Italy, the UK, and France, with one portfolio company — Herbolea — maintaining operations in both Italy and the United States.
How can an external investor access Óskare Capital's strategy?
Óskare Capital is currently raising Oskare Fund I, its dedicated venture vehicle. The firm invites inquiries through its website for those interested in investing in the fund or its portfolio companies.
Does Óskare Capital participate in fund commitments or only direct deals?
Based on disclosed activity, the firm exclusively executes direct venture investments into operating companies. No fund-of-fund commitments or LP positions in other managers are publicly noted.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on venture capital firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: